Kyverna Shares Jump 27% After Positive Topline Data From CAR-T Autoimmune Study

(RTTNews) - Kyverna Therapeutics, Inc. (KYTX) surged 27.45%, gaining $2.41 to trade at $11.19, after the company announced positive topline clinical data supporting the potential of its CAR-T cell therapy program in autoimmune disease.

The company reported that the study met key objectives, demonstrating encouraging efficacy signals and a safety profile consistent with expectations for autologous CAR-T therapies. Management said the results reinforce Kyverna's strategy of applying CAR-T technology beyond oncology and into severe autoimmune indications, where treatment options remain limited.

The update strengthens Kyverna's clinical position as it prepares for further data disclosures, regulatory interactions, and potential advancement of the program into later-stage development.

KYTX trades within a 52-week range of approximately $6.90 - $14.80.

The sharp move reflects renewed investor confidence in Kyverna's pipeline and the broader potential for CAR-T therapies in autoimmune disease settings.